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Abstract
Setting
Primary health services in Cape Town, South Africa where the introduction of Xpert® MTB/
RIF (Xpert) enabled simultaneous screening for tuberculosis (TB) and drug susceptibility in
all presumptive cases.
Study aim
To compare the proportion of TB cases with drug susceptibility tests undertaken and multi-
drug-resistant tuberculosis (MDR-TB) diagnosed pre-treatment and during the course of
1st line treatment in the previous smear/culture and the newly introduced Xpert-based
algorithms.
Methods
TB cases identified in a previous stepped-wedge study of TB yield in five sub-districts over
seven one-month time-points prior to, during and after the introduction of the Xpert-based
algorithm were analysed. We used a combination of patient identifiers to identify all drug
susceptibility tests undertaken from electronic laboratory records. Differences in the propor-
tions of DST undertaken and MDR-TB cases diagnosed between algorithms were estimated
using a binomial regression model.
Results
Pre-treatment, the probability of having a DST undertaken (RR = 1.82)(p<0.001) and being
diagnosed with MDR-TB (RR = 1.42)(p<0.001) was higher in the Xpert-based algorithm
than in the smear/culture-based algorithm. For cases evaluated during the course of 1st-line
TB treatment, there was no significant difference in the proportion with DST undertaken (RR
= 1.02)(p = 0.848) or MDR-TB diagnosed (RR = 1.12)(p = 0.678) between algorithms.
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Conclusion
Universal screening for drug susceptibility in all presumptive TB cases in the Xpert-based
algorithm resulted in a higher overall proportion of MDR-TB cases being diagnosed and is
an important strategy in reducing transmission. The previous strategy of only screening
new TB cases when 1st line treatment failed did not compensate for cases missed pre-
treatment.
Introduction
Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to rifampicin and isoniazid,
presents a major global health challenge with an estimated 480,000 incident cases in 2014 [1].
Whilst MDR-TB rates are substantially higher among previously treated cases (20%) than
among new cases (3.3%), the latter contribute substantially to the total burden, accounting for
an estimated 53% of MDR-TB cases among the pulmonary TB cases notified in 2014 [1]. The
high proportion of new TB cases with MDR-TB (primary MDR-TB) suggests significant dis-
ease transmission.
Persistent diagnostic gaps due to both inadequate TB case-detection and limited drug sus-
ceptibility testing among detected cases contribute to transmission of MDR-TB. Only 6 million
of the estimated 9.6 million TB cases in 2014 were detected. Among notified pulmonary TB
cases, 300,000 were estimated to have MDR-TB; however just 12% of new and 58% of previ-
ously treated cases were tested for drug susceptibility and 123,000 MDR-TB cases were notified
globally [1]. Thus it is estimated that 180,000 of the missed MDR-TB cases were among those
with undetected TB and 177,000 among detected TB cases not screened for drug susceptibility.
The past reliance on insensitive smear microscopy tests [2–4] as the cornerstone of labora-
tory diagnosis has contributed to poor TB case-detection, particularly among human immu-
nodeficiency virus (HIV)-infected cases, where sensitivity can be as low as 23% to 50% [5–9].
Limited laboratory capacity for culture and drug susceptibility testing (DST) contributes to
poor MDR-TB case-detection: among the 36 high TB or MDR-TB burden countries, only 16
met the benchmark of one laboratory with culture and DST capabilities per five million popu-
lation in 2010 [10]. In many developing countries these limitations have led to DST being
rationed for use among previously treated cases as they are most at risk of MDR-TB [11–13].
The availability of the more sensitive Xpert1 MTB/RIF (Xpert)(Cepheid, Sunnyvale, CA,
USA) test offers the possibility of improving TB case-detection and simultaneously screening
for drug susceptibility. Xpert is a nucleic acid amplification test that detects genetic sequences
for Mycobacterium tuberculosis (MTB) complex and simultaneously, the presence of ‘wild type’
or mutations conferring resistance to rifampicin. Xpert has the ability to detect low bacteria
loads (limit of detection 131 colony forming units (CFU) per ml) [14] compared to 10,000
CFU per ml for smear [15]) and is particularly useful in diagnosing the smear-negative TB typ-
ically found in HIV-infected individuals. Xpert has high sensitivity and specificity for detecting
both TB and rifampicin resistance. In a meta-analysis of fifteen studies where Xpert was used
as the initial test replacing smear microscopy, pooled sensitivity was 88% (95%CrI 83% to
92%) and specificity was 98% (95% CrI 97% to 99%) for detecting MTB. In eleven of these
studies, pooled sensitivity was 94% (95% CrI 87% to 97%) and specificity was 98% (95% CrI
97% to 99%) for rifampicin resistance [16].
While Xpert has the technical capacity to help close MDR-TB diagnostic gaps, very little has
been reported on its use in universal drug susceptibility screening under routine operational
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conditions. A study in India found that routine, up-front use of Xpert in children under
14-years of age almost tripled the number of Rif-R cases diagnosed (from 22 to 60 among the
8,370 presumptive TB cases screened), than would have been achieved through screening of
presumptive DR-TB cases only [17].
Our study compared the proportion of TB cases with DST undertaken and MDR-TB diag-
nosed pre-treatment in the previous smear/culture-based algorithm and the newly introduced
Xpert-based algorithm. Among cases without MDR-TB diagnosed pre-treatment, we com-
pared the proportion with DST undertaken and MDR-TB diagnosed during the course of 1st-
line TB treatment. Comparisons were made for new and previously treated TB cases. The
study was part of PROVE IT (Policy Relevant Outcomes from Validating Evidence on
ImpacT), an evaluation to assess the impact of new molecular diagnostics on TB and MDR-TB
diagnosis and treatment initiation in a routine operational context.
Methods
We had previously undertaken and published results of a non-randomised stepped-wedge
study to assess TB yield [18]. The current study assessed drug susceptibility screening and
MDR-TB diagnosis among the TB cases identified in the previous study. Some details are
highlighted here for completeness.
Setting
The study was undertaken in Cape Town, South Africa where free TB diagnostic services were
provided at 142 primary health care (PHC) facilities in eight health sub-districts. Prior to
August 2011, a smear/culture-based diagnostic algorithm was used (Fig 1). All presumptive TB
cases were evaluated through two spot sputum specimens, taken 1-hour apart and examined
by fluorescence microscopy. In previously treated TB cases, those from congregate settings or
with an MDR-TB contact, the second specimen also underwent liquid culture (BACTEC™
MGIT™ 960) and DST with GenoType1 MTBDRplus (Hain LifeScience GmbH, Nehren, Ger-
many) line probe assay (LPA).
Between August 2011 and February 2013 an Xpert-based algorithm was phased into the
eight health sub-districts with Xpert replacing smear microscopy for all (new and previously
treated) presumptive TB cases (Fig 1). The first of two sputum specimens submitted was tested
with Xpert; if rifampicin resistance was detected, the second specimen underwent smear, cul-
ture and LPA.
In both algorithms, new and previously treated cases in which first line TB treatment regi-
mens failed had specimens submitted for culture and LPA during the course of treatment.
Routine TB Programme data collected during the study period, indicated that the number
of notified TB cases declined from 28,644 in 2011 (752/100,000 population) to 25,846 in 2013
(663/100,000 population). HIV co-infection rates were 47% (97% tested) and 44% (98% tested)
in respective years. The number of MDR-TB cases notified increased from 1,020 to 1,134,
comprising 3.6% and 4.4% of TB cases respectively (Routine TB Programme Data, Cape Town
Health Directorate, April 2016).
Definitions
A presumptive TB case was defined as an individual with pre-treatment sputum samples sub-
mitted for diagnostic purposes.
A TB case was defined as an individual with one or more smears positive and / or culture
positive for MTB and / or MTB detected on Xpert. TB cases were categorised as new (an
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individual with no or less than four weeks of previous TB treatment) or previously treated (an
individual with more than four weeks of previous TB treatment).
An MDR-TB case was defined as a TB case with rifampicin resistance on LPA or Xpert,
diagnosed either pre-treatment or whilst on 1st line TB treatment. Rifampicin resistance was
used as a proxy indicator of MDR-TB.
Study design, timeframes and population
The previously published stepped-wedge study assessed TB yield in five sub-districts over
seven one-month time-points (T1 to T7) prior to, during and after the introduction of the
Xpert-based algorithm [18]. The current study population included all presumptive TB cases
with a bacteriological diagnosis of TB in the smear/culture-based algorithm (T1 to T5) and in
the Xpert-based algorithm (T3 to T7) (Fig 2).
Data sources & management
The National Health Laboratory Services provided TB test data from the electronic laboratory
database for 2010–2014. Data included clinic identification, patient clinical folder number,
patient demographics, TB category (new, previously treated), test type (smear, culture, LPA
or Xpert), diagnostic point (pre-treatment or on 1st-line treatment), test date and result.
Fig 1. Testing in the smear/culture and Xpert-based TB diagnostic algorithms. The sequence of diagnostic tests in each algorithm and the
action taken based on test results is shown. Shaded blocks indicate possible MDR-TB diagnostic points. Abbreviations: MDR-TB—multidrug-
resistant tuberculosis; LPA—GenoType® MTBDRplus line probe assay; DST—drug susceptibility testing; HIV–human immunodeficiency virus;
Rif–rifampicin; Pos–positive.
doi:10.1371/journal.pone.0172143.g001
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Laboratory data for all primary health facilities and all hospitals in Cape Town were
imported into Microsoft SQL. We used a combination of patient name, surname, birth date,
address and clinical folder number to identify all DSTs undertaken (i.e. a rifampicin result on
Xpert / LPA) for the TB cases diagnosed at T1 to T7 and to identify duplicates cases (individu-
als diagnosed at multiple facilities). DSTs were classified as pre-treatment if recorded as a pre-
treatment test or if taken within 7 days of this test. DSTs were classified as taken during 1st line
treatment if taken >7 days and up to 9 months after the pre-treatment test. All matches and
classification as “pre-treatment” or “treatment” were manually verified.
Data analysis
Cases were allocated to algorithm based on the algorithm in place at the facility at the time-
point i.e. we used an intention to treat approach in the analysis. We compared the proportion
of TB cases with DST undertaken and MDR-TB diagnosed pre-treatment in the smear/cul-
ture-based algorithm and the Xpert-based algorithm. Among cases without MDR-TB diag-
nosed pre-treatment, we assessed the proportion with DST undertaken and MDR-TB
diagnosed during the course of 1st-line TB treatment in both algorithms. Analyses were done
for new and for previously treated TB cases.
Descriptive data are presented using proportions and frequencies. Normally distributed
continuous outcomes were analysed using the t-test and categorical outcomes using the chi-
squared test. A binomial regression model, adjusted for clustering at 60 primary health care
sites, was used to estimate differences in the proportions of DST undertaken and MDR-TB
cases diagnosed between algorithms and the interaction of age, gender and treatment category
variables. We undertook a sub-analysis for new and previously treated cases. We did not
Fig 2. TB cases from the stepped-wedge analysis of TB yield included in this analysis. This figure shows the TB diagnostic algorithm in place in
5 groups of PHC sites over seven time-points (T1 to T7) during the transition from the smear/culture-based algorithm to the Xpert-based algorithm. All
TB cases identified in the smear culture-based algorithm (T1 to T5) and in the Xpert-based algorithm (T3 to T7) were included in the current analysis. A
PHC site consisted of municipal and provincial health facilities linked to their satellite and mobile facilities and to each other if within a single geographic
location (to account for shared diagnostic services). Abbreviations: PHC = primary health care.
doi:10.1371/journal.pone.0172143.g002
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consider a time-effect, as the change in the proportion with DST undertaken over time was
inherent to the phased introduction of the Xpert-based algorithm. All analyses were under-
taken using STATA 13 (StataCorp).
Ethics statement
The Health Research Ethics Committee at Stellenbosch University (IRB0005239) (N10/09/
308) and Ethics Advisory Group at The International Union Against Tuberculosis and Lung
Disease (59/10) approved the study. A waiver of informed consent was granted for the use of
routine data. The City Health Directorate, Western Cape Health Department and National
Health Laboratory Service granted permission to use routine health data. Data sharing is possi-
ble following approval by these authorities.
Results
A total of 5,019 TB cases were diagnosed in the smear/culture-based algorithm and 5,444 in
the Xpert-based algorithm. Among these, 7 and 3 cases were excluded from respective algo-
rithms as they were known MDR/XDR-TB cases (with tests incorrectly reported as pre-treat-
ment) and 97 and 72 from respective algorithms were merged with corresponding records as
they belonged to individuals diagnosed at multiple facilities. The remaining 4,915 TB cases in
the smear/culture group and 5,369 in the Xpert group were included in the analysis.
Characteristics of TB cases and those with DST undertaken by algorithm
There were no significant differences in age, gender or TB category (new or previously treated)
between TB cases in the smear/culture and Xpert groups (Table 1). For those with DST
Table 1. Characteristics of TB cases evaluated by algorithm. The smear/culture and Xpert groups were compared using chi-squared tests. Missing val-
ues are not shown but have been included in the calculation of percentages. These have been excluded when comparing groups and calculating p-values.
Abbreviations: TB–tuberculosis; DST–drug susceptibility test; SD–standard deviation.
Smear/culture-based
algorithm
Xpert-based
algorithm
p-value
TB cases Total 4,915 5,369 -
Mean age (Years) [SD] 35 [13] 35 [12] 0.905
Number male (%) 2,702 (55) 2,995 (56) 0.811
Number female (%) 2,086 (42) 2,290 (43)
Number new cases (%) 2,990 (61) 3,322 (62) 0.309
Number previously treated cases
(%)
1,490 (30) 1,583 (29)
DST undertaken pre-treatment Total 2,099 4,235 -
Mean age (Years) [SD] 36 [11] 35 [12] 0.043
Number male (%) 1,165 (56) 2,396 (57) 0.784
Number female (%) 879 (42) 1,781 (42)
Number new cases (%) 946 (45) 2,733 (65) <0.001
Number previously treated cases
(%)
1015 (48) 1,253 (30)
DST undertaken for cases on 1st line TB
treatment
Total 221 247 -
Mean age (Years) [SD] 35 [12] 37 [11] 0.135
Number male (%) 122 (55) 164 (66) 0.013
Number female (%) 96 (43) 80 (32)
Number new cases (%) 102 (46) 122 (49) 0.469
Number previously treated cases
(%)
101 (46) 105 (43)
doi:10.1371/journal.pone.0172143.t001
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undertaken pre-treatment, cases in the smear/culture group were slightly older and contained
a lower proportion of new cases (45% compared to 65% in the Xpert group). Among those
with DST undertaken on treatment, the smear/culture group contained a higher proportion of
females (43% compared to 32% in the Xpert group).
Proportion of TB cases with drug susceptibility testing and MDR-TB
diagnosed by algorithm
DSTs were undertaken pre-treatment for 42.7% of TB cases in the smear/culture group com-
pared to 78.9% in the Xpert group and 5.5% and 7.7% of TB cases in respective groups had
MDR-TB diagnosed (Table 2). Among cases not initially diagnosed with MDR-TB, 4.8% and
5.0% in respective groups had DST undertaken during the course of 1st-line TB treatment and
0.6% and 0.9% respectively were diagnosed with MDR-TB. In these MDR-TB cases, a lower
proportion of cases had received an initial pre-treatment DST in the smear/culture group
(5/28) than in the Xpert group (21/43)(p = 0.008).
Among new TB cases, DSTs were undertaken pre-treatment for 31.6% of TB cases in the
smear/culture group compared to 82.3% in the Xpert group and 2.7% and 5.5% of new TB
cases in respective groups had MDR-TB. Among new TB cases not initially diagnosed with
MDR-TB, similar proportions had DST undertaken (3.5% and 3.9% respectively) and were
diagnosed with MDR-TB (0.3% and 0.5% respectively) during the course of 1st-line TB
treatment.
Among previously treated TB cases, DSTs were undertaken pre-treatment for 68.1% of TB
cases in the smear/culture group compared to 79.2% in the Xpert group and 10.6% and 11.5%
of previously treated TB cases in respective groups had MDR-TB diagnosed. Among previ-
ously treated TB cases not initially diagnosed with MDR-TB, similar proportions had DST
undertaken (7.6% and 7.5% respectively) and were diagnosed with MDR-TB (1.4% in both
algorithms) during the course of 1st-line TB treatment.
Comparing TB cases with DST undertaken pre-treatment and MDR-TB
diagnosed by algorithm
The probability of having a DST undertaken pre-treatment was 1.82 times higher in the Xpert
group than in the smear/culture group (p<0.001)(Table 3). Previously treated TB cases were
more likely to have DST undertaken (RR = 1.09, p = 0.001) than new cases.
Table 2. Drug susceptibility testing and MDR-TB cases diagnosed by TB diagnostic algorithm. Data is not shown for cases with TB category
“unknown” (435 cases (8.9%) in smear/culture group and 464 (8.6%) in Xpert group) but can be calculated based on the numbers shown. DST (drug suscepti-
bility tests) and MDR-TB (multidrug- resistant tuberculosis) pre-treatment are expressed as a percentage of TB cases. DST and MDR-TB on 1st line TB treat-
ment are expressed as a percentage of TB cases not initially diagnosed with MDR-TB. Abbreviations: TB–tuberculosis; MDR-TB—multidrug-resistant
tuberculosis.
Smear/culture-based algorithm Number of cases
(%)
Xpert-based algorithm Number of cases (%)
All TB
cases
New TB
cases
Previously treated
cases
All TB
cases
New TB
cases
Previously treated
cases
Number of TB cases 4915 2990 1490 5369 3322 1583
DST undertaken pre-treatment 2099 (42.7) 946 (31.6) 1015 (68.1) 4235 (78.9) 2733 (82.3) 1253 (79.2)
MDR-TB diagnosed pre-treatment 269 (5.5) 82 (2.7) 158 (10.6) 415 (7.7) 184 (5.5) 182 (11.5)
DST undertaken on 1st line TB
treatment
221 (4.8) 102 (3.5) 101 (7.6) 247 (5.0) 122 (3.9) 105 (7.5)
MDR-TB diagnosed on 1st line TB
treatment
28 (0.6) 9 (0.3) 18 (1.4) 43 (0.9) 15 (0.5) 20 (1.4)
Total MDR-TB diagnosed 297 (6.0) 91 (3.0) 176 (11.8) 458 (8.5) 199 (6.0) 202 (12.8)
doi:10.1371/journal.pone.0172143.t002
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The likelihood of being diagnosed with MDR-TB was 1.42 times higher in the Xpert group
than in the smear/culture group (p<0.001). Previously treated cases were more likely to be
diagnosed with MDR-TB pre-treatment than new cases (RR = 2.67, p<0.001).
Among new TB cases, the likelihood of a DST being undertaken pre-treatment was 2.64
times higher (p<0.001) and of MDR-TB being diagnosed was 2.09 times higher (p<0.001) in
the Xpert group than in the smear/culture group. Among previously treated TB cases, the like-
lihood of a DST being undertaken pre-treatment was 1.15 times higher in the Xpert group
than in the smear/culture group (p<0.001); however, the risk of being diagnosed with
MDR-TB was not increased (RR = 1.09, p = 0.376).
Comparing cases with DST undertaken whilst on 1st line TB treatment
by algorithm and MDR-TB diagnosed
Among TB cases not initially diagnosed with MDR-TB, there was no significant difference in
the proportion with DST undertaken during the course of 1st-line TB treatment in the Xpert
Table 3. Comparison of TB cases with DST undertaken pre-treatment and MDR-TB diagnosed. The table shows outputs from binomial regression
models for all TB cases with drug susceptibility tests (DST) undertaken pre-treatment and multidrug-resistant tuberculosis (MDR-TB) diagnosed and for sub-
categories of new and previously treated cases. Facility level clustering has been taken into account in the binomial regression models. Abbreviations: TB–
tuberculosis; MDR-TB—multidrug-resistant tuberculosis
Variable Risk ratio Standard error 95% CI p-value
All TB cases
DST undertaken Xpert-based algorithm 1.82 0.07 1.69 to 1.97 <0.001
Age ~1.00 <0.01 1.00 to 1.00 0.037
Female gender 0.98 0.01 0.96 to 1.00 0.052
Previously treated category 1.09 0.03 1.03 to 1.14 0.001
Constant 0.46 0.02 0.41 to 0.50 <0.001
MDR-TB diagnosed Xpert-based algorithm 1.42 0.13 1.19 to 1.70 <0.001
Age 0.99 <0.01 0.99 to <1.00 0.008
Female gender 1.09 0.10 0.91 to 1.30 0.335
Previously treated category 2.67 0.27 2.19 to 3.25 <0.001
Constant 0.05 0.01 0.03 to 0.06 <0.001
New TB cases
DST undertaken Xpert-based algorithm 2.64 0.19 2.29 to 3.05 <0.001
Age 1.00 <0.01 1.00 to 1.00 0.129
Female gender 0.97 0.02 0.94 to 1.00 0.091
Constant 0.33 0.03 0.28 to 0.38 <0.001
MDR-TB diagnosed Xpert-based algorithm 2.09 0.33 1.53 to 2.84 <0.001
Age 0.99 <0.01 0.98 to <1.00 0.088
Female gender 1.03 0.15 0.78 to 1.36 0.821
Constant 0.04 <0.01 0.02 to 0.05 <0.001
Previously treated TB cases
DST undertaken Xpert-based algorithm 1.15 0.03 1.10 to 1.21 <0.001
Age 1.00 <0.01 1.00 to 1.00 0.024
Female gender 0.99 0.02 0.94 to 1.03 0.553
Constant 0.76 0.03 0.70 to 0.83 <0.001
MDR-TB diagnosed Xpert-based algorithm 1.09 0.11 0.90 to 1.34 0.376
Age 0.99 <0.01 0.98 to 1.00 0.047
Female gender 1.15 0.13 0.91 to 1.43 0.237
Constant 0.14 0.03 0.10 to 0.20 <0.01
doi:10.1371/journal.pone.0172143.t003
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group (RR = 1.02; p = 0.848) compared to with smear/culture group (Table 4). Females were
less likely to be screened for drug susceptibility than males (RR = 0.77; p = 0.015). Previously
treated TB cases were more likely to be screened for drug susceptibility than new cases
(RR = 2.02, p<0.001).
The likelihood of being diagnosed with MDR-TB during the course of 1st-line TB treat-
ment was similar in the Xpert (RR = 1.12; p = 0.678) and smear/culture groups. Previously
treated TB cases were 3.96 times more likely to be diagnosed with MDR-TB than new cases
(p <0.001).
Discussion
Previously treated TB cases are at significantly higher risk of MDR-TB than new cases [11–13].
Many countries including South Africa have historically rationed the use of DST in favour of
these cases. Thus, in the previous smear/culture-based algorithm drug-susceptibility testing in
presumptive TB cases was limited to those at high risk of MDR-TB, namely those who were
previously treated for TB, with MDR-TB contacts or from congregate settings. The assumption
was that the smaller proportion of new TB cases with drug resistance would be detected during
the course of 1st-line treatment.
In comparison, the Xpert-based algorithm required all presumptive TB cases to be screened
with Xpert. As expected, our study found that a higher proportion TB cases were screened for
drug susceptibility pre-treatment in the Xpert-based algorithm (78.9%) compared to in the
smear/culture-based algorithm (42.7%). Overall, TB cases were 82% more likely to be screened
for drug susceptibility and 42% more likely to be diagnosed with MDR-TB pre-treatment in
the Xpert-based algorithm than in the smear/culture-based algorithm. These differences were
accentuated among new cases (RR = 2.64 for DST and RR = 2.09 for MDR-TB). Although pre-
viously treated cases were also more likely to have a DST in the Xpert-based algorithm
(RR = 1.15) there was no significant increase in the likelihood of an MDR-TB diagnosis.
Interestingly, similar proportions of cases were screened for drug susceptibility (RR = 1.02;
p = 0.848) and identified with MDR-TB (R = 1.12; p = 0.678) during the course of 1st-line TB
treatment in the Xpert-based algorithm compared to in the smear/culture-based algorithm.
The assumption that new cases with MDR-TB that were initially missed in the smear/culture-
based algorithm would be picked up during the course of treatment appears not to hold true.
We speculate that there may have been cases that died or were lost to follow-up before the
opportunity to screen them for drug resistance presented.
Table 4. Comparison of TB cases with DST undertaken whilst on 1st line TB treatment and MDR-TB diagnosed. This table shows outputs from a bino-
mial regression model for all TB cases with drug susceptibility tests (DST) undertaken and for multidrug-resistance tuberculosis (MDR-TB) diagnosed during
the course of 1st-line TB treatment. Facility level clustering has been taken into account in the models.
Variable Risk ratio Standard error p-value 95% CI
DST undertaken Xpert-based algorithm 1.02 0.13 0.848 0.80 to 1.31
Age 1.00 <0.01 0.760 0.99 to 1.00
Female gender 0.77 0.08 0.015 0.62 to 0.95
Previously treated cases 2.02 0.25 <0.001 1.59 to 2.58
Constant 0.04 <0.01 <0.001 0.03 to 0.06
MDR-TB diagnosed Xpert-based algorithm 1.12 0.34 0.678 0.63 to 2.03
Age 0.99 <0.01 0.435 0.98 to 1.01
Female gender 0.84 0.22 0.520 0.50 to 1.41
Previously treated cases 3.86 0.84 <0.001 2.52 to 5.90
Constant <0.01 <0.01 <0.001 <0.01 to 0.01
doi:10.1371/journal.pone.0172143.t004
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It is notable that women were less likely to have a DST undertaken during the course of 1st
line TB treatment than men. It is difficult to know whether this is due to reduced perceptions
of risk (perhaps due to better adherence to treatment) or to women receiving a poorer quality
of service [19–23].
There were over double the number of new compared to previously treated TB cases in the
Xpert-based algorithm. Although the proportion of MDR-TB is higher among previously
treated TB cases than among new cases, the large number of new TB cases means that they
contributed almost equally to the number of MDR-TB cases diagnosed pre-treatment with
Xpert. Failure to identify these cases early has serious consequences. It contributes to ongoing
transmission of MDR-TB which is substantially more expensive [24] and difficult to treat suc-
cessfully [25]. Inappropriate treatment leads to amplification of drug resistance [26,27] and
exacerbates costs [24] and poor treatment outcomes [25]. The direct impact on patients of fail-
ing to identify MDR-TB pre-treatment should not be under-estimated. Interviews undertaken
as part of PROVE IT illustrated the physical and emotional suffering endured by patients
when 1st line TB regimens failed, how socio-economic difficulties were compounded and the
devastating impact on families, particularly when children were infected [28,29].
Strengths and limitations
The strength of an operational evaluation is that it reflects the reality of routine practice,
including the impact of inconsistent implementation of diagnostic procedures. The evaluation
was undertaken in the early phase of Xpert implementation which may have contributed to
sub-optimal implementation of this algorithm, as not all presumptive TB cases received an
Xpert test as required, resulting in an under-estimation of effect. However, even in the well-
entrenched smear/culture-based algorithm, fewer previously treated cases had DST under-
taken as required than in the newly introduced Xpert-based algorithm.
A major strength of the study was that we were had retrospective data that enabled us to
assess DST undertaken during the course of treatment. This allowed us to assess whether lim-
ited initial DST and MDR-TB diagnosis was compensated by screening and diagnosis during
the course of 1st-line TB treatment; we found this not to be the case.
The completeness of routine data, with missing age (<5%), gender (<3%) and treatment
category (<9%) variables in both groups is a limitation but is unlikely to have influenced over-
all findings at these levels. We were unable to analyse the interaction of HIV as this data was
not available in the electronic laboratory dataset.
Our case definitions did not take account of discordant Rif-R results. Among the 223 cases
with Rif-R on Xpert, 24 did not have confirmatory LPA and 12 had a discordant first LPA
result (the majority of these did not have further tests undertaken). This may have resulted in
an over-estimation of the proportion of true positive Rif-R cases in the Xpert-based algorithm.
An intention to treat approach was adopted with the analysis based on the algorithm in place
at the facility and not the tests undertaken. During the transition between algorithms, some
contamination occurred with facilities in the smear/culture based algorithm testing patients
via Xpert, resulting in a slight over-estimation of pre-treatment DST undertaken (additional
102 cases) and MDR-TB cases diagnosed (additional 3 cases).
Implications for policy and practice
Overall 8.5% of TB cases were detected with MDR-TB in the Xpert-based algorithm compared
to 6% in the smear/culture-based algorithm. If one applies these proportions to the approxi-
mately 15,000 bacteriologically diagnosed PTB cases in all eight sub-districts in Cape Town
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annually, it translates to a substantial programmatic effect–an additional 375 MDR-TB cases
diagnosed annually.
A recent national DR-TB prevalence survey in South Africa reported high rates of rifampi-
cin resistance—3.4% among new cases and 7.1% among previously treated cases in 2012–2014
[30], confirming high rates of transmission and a substantial national burden. The use of
Xpert MTB/RIF as a screening tool for all presumptive TB cases is important in detecting these
cases and reducing transmission, but comes at a high cost. A laboratory costing study under-
taken as part of PROVE-IT reported an incremental cost-effectiveness ratio of $6,274 per
MDR-TB case identified in the Xpert-based algorithm [31].
In addition to identifying patients with MDR-TB, reduced transmission will also be influ-
enced by the proportion who initiate treatment, treatment delay and treatment success. Rou-
tine data from South Africa shows that only 62% of detected MDR-TB cases (11,538/18,734)
initiated treatment in 2014 [1]. Whilst studies have reported reductions in delay from MDR-
TB diagnosis to treatment [32,33], pre-diagnostic delays are unknown. Two systematic reviews
in TB patients reported average (mean or median) time delays from symptom onset to first
health care visit of 5–162 days [34] and 7–69 days [35] respectively. These may well be longer
for MDR-TB patients. Treatment success rates are dismal: MDR-TB treatment success rates of
39% were reported for cases registered nationally in 2009–2011 [25). Decentralised treatment
models also reported low success rates: 52% in a study in the Western Cape [36] and in Kwa-
Zulu Natal, 54% from centralised treatment compared to 58% from decentralised treatment
[37]. Health system improvements, appropriate support for patients and improved regimens
are required to improve treatment initiation, adherence and outcomes in order to help reduce
MDR-TB transmission.
Conclusion
Universal drug susceptibility testing (i.e. among all presumptive TB cases) in the Xpert-based
algorithm detected a significantly higher proportion of MDR-TB cases than the rationed
approach used in the smear/culture-based algorithm. The previous strategy of only screening
new TB cases when 1st line treatment failed did not compensate for cases missed pre-treat-
ment. However, universal screening with Xpert is an expensive strategy–in order to justify this
expenditure, patient and diagnostic delays must be decreased; health services strengthened
and new treatment regimens introduced to improve MDR-TB treatment initiation and out-
comes. The cost of Xpert needs to be reduced to ensure sustainability.
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